Q-omics provides the consensus-scored LINC00609 profile across patient tissues and cancer cell-line models. LINC00609 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC00609 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, LINC00609 RNA expression shows 11,414 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, THCA, and GBM as cancer lineages where LINC00609 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00609 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00609 survival associations across molecular data types. LINC00609 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00609 RNA expression–survival associations across cancer types. High LINC00609 expression shows unfavorable associations in BLCA, ACC, THYM, KIRP and HNSC, but favorable associations in LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC00609 RNA expression.
This table summarizes LINC00609 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00609. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00609 shows lower tumor expression in THCA, KICH, KIRC and KIRP and higher tumor expression in BRCA. The THCA box plot shows higher LINC00609 RNA expression in normal versus tumor tissue (log2 FC = −1.278, t-test p < 0.001).
This table shows molecular features associated with LINC00609 in patient tissues and cancer cell lines. In patient samples, LINC00609 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
